![](/wp-content/uploads/2018/10/qZuPOp2TbmDwYytVOuH3.png)
$599
Farxiga Receives Breakthrough Therapy Designation for CKD
AstraZeneca announced FDA granted Breakthrough Therapy Designation (BTD) to Farxiga for the treatment of chronic kidney disease in patients with and without diabetes. Below, FENIX provides thoughts on the impending DAPA-CKD regulatory review in the context of Janssen’s CREDENCE and readthrough to BI/Lilly’s EMPA-KIDNEY.